ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,307.01
-0.27%
Dow Jones
39,671.04
-0.51%
US Dollar vs MXN
16.6551
-0.06%
Brent Oil
81.275
-0.31%
Bitcoin
69,482.13
0.55%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) Noticias

VKTX

Viking Therapeutics (VKTX)

Viking Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VKTX
FechaHoraFuenteTítuloSímboloCompañía
22/05/202416:12Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:VKTXViking Therapeutics Inc
22/05/202415:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
24/04/202415:05PR Newswire (US)Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
24/04/202406:31IH Market NewsU.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures TradingNASDAQ:VKTXViking Therapeutics Inc
17/04/202415:05PR Newswire (US)Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024NASDAQ:VKTXViking Therapeutics Inc
26/03/202406:03PR Newswire (US)Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735NASDAQ:VKTXViking Therapeutics Inc
04/03/202418:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
04/03/202415:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
04/03/202415:45PR Newswire (US)Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:VKTXViking Therapeutics Inc
01/03/202415:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
28/02/202419:50PR Newswire (US)Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202415:19PR Newswire (US)Viking Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202406:03PR Newswire (US)Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
09/02/202415:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
07/02/202416:24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VKTXViking Therapeutics Inc
07/02/202415:05PR Newswire (US)Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
31/01/202415:05PR Newswire (US)Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024NASDAQ:VKTXViking Therapeutics Inc
13/11/202315:02PR Newswire (US)Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023NASDAQ:VKTXViking Therapeutics Inc
02/11/202315:03PR Newswire (US)Viking Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:VKTXViking Therapeutics Inc
25/10/202316:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VKTXViking Therapeutics Inc
25/10/202315:05PR Newswire (US)Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
23/10/202306:05PR Newswire (US)Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
18/10/202315:05PR Newswire (US)Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023NASDAQ:VKTXViking Therapeutics Inc
18/10/202308:06IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:VKTXViking Therapeutics Inc
18/10/202308:03IH Market NewsWednesday’s Wall Street Highlights: ASML, Nvidia, United Airlines, Viking Therapeutics, P&G, and MoreNASDAQ:VKTXViking Therapeutics Inc
17/10/202315:05PR Newswire (US)Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023NASDAQ:VKTXViking Therapeutics Inc
10/10/202315:05PR Newswire (US)Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023NASDAQ:VKTXViking Therapeutics Inc
06/09/202306:03PR Newswire (US)Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
26/07/202316:26Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VKTXViking Therapeutics Inc
26/07/202315:05PR Newswire (US)Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VKTX

Su Consulta Reciente

AMEX
AXN
NYSE
AVI
NASDAQ
FSQNIX
Global Commodities Oppor...
ASX
ARFDC
USOTC
NISUY
Nissui (PK)
EU
GB00B3KJDS62
Treasury 4 25%tsy Gilt 7...
EU
THAAJ
THALES SA 0.250% until 2...
AMEX
PLMRW
PolyMet Mining
LSE
37YM
Investec Bnk 24
NYSE
RF-A
Regions Financial
NYSE
TXO
TXO Partners
COIN
PINKUST
PinkCoin
TSX
IAF.PR.G
Industrial Alliance Insu...
COIN
UOPUSD
Utopia Open Platform
BOV
A1IV34M
Apartment Investment & M...
NASDAQ
AAZWHXX
Ubs Ag London Branch Itm...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados